Journal
CURRENT ONCOLOGY
Volume 22, Issue 6, Pages E498-E501Publisher
MULTIMED INC
DOI: 10.3747/co.22.2700
Keywords
Medical oncology; breast cancer
Categories
Funding
- Pfizer
- Incyte
Ask authors/readers for more resources
Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer. Patients with loss of CDKN2A (p16), an inherent negative regulator of cyclin-dependent kinases 4 and 6, were not separately studied because of the significant response of the patients selected based only on receptor status. Here, we report a patient with metastatic estrogen receptor-positive, HER2-negative breast cancer with CDKN2A loss who experienced a clinical response to palbociclib.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available